Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05079282 · ClinicalTrials.gov registry record · Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
A Phase 1 study of Relapsed or Refractory T Cell Lymphoma, sponsored by Ono Pharmaceutical Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 217
- Enrollment target
- 20
- Study locations
NCT05079282 is a Phase 1 study of Relapsed or Refractory T Cell Lymphoma that is actively recruiting participants, run by Ono Pharmaceutical Co.. The registered enrollment target is 217 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT05079282, a Phase 1 study of Relapsed or Refractory T Cell Lymphoma, is actively recruiting participants, sponsored by Ono Pharmaceutical Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 217 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
Conditions Studied
Interventions
- DRUG ONO-4685
Study Locations (20)
California
- City of Hope - Duarte
- University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center - Orange
- Stanford Cancer Institute - Palo Alto
New York
- Roswell Park Cancer Institute - Buffalo
- New York-Presbyterian/Columbia University Irving Medical Center - Herbert Irving Comprehensive Cancer Center (HICCC) - New York
- Memorial Sloan-Kettering Cancer Center - New York
Texas
- UT Southwestern Medical Center - Dallas
- MD Anderson - Houston
Alabama
- University of Alabama at Birmingham - Birmingham
Connecticut
- Yale Cancer Center - New Haven
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2021-12-10 |
| Est. Completion | 2028-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05079282
The ClinicalTrials.gov registry entry for NCT05079282 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ono Pharmaceutical Co., which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory T Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which ONO-4685 is the first listed.
NCT05079282 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT05079282 about?
NCT05079282 is a clinical study titled "Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma". This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
What is the current status of trial NCT05079282?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 217 participants. The study started on 2021-12-10. Estimated completion is 2028-08-31.
What conditions does trial NCT05079282 study?
This clinical trial studies the following conditions: Relapsed or Refractory T Cell Lymphoma.
What interventions are being tested in trial NCT05079282?
The interventions under investigation include: ONO-4685 (DRUG).
Who is sponsoring clinical trial NCT05079282?
This trial is sponsored by Ono Pharmaceutical Co., which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05079282 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.